We incorporate multiple years of experience in building life sciences companies and researching biosensors.

lino's Founder Team

After several years of research in the focal molography field and development of an own biosensor platform, lino Biotech AG 2020 was founded.

With the support of Hoffman-La Roche AG, we are bringing the benefits of focal molography to the drug discovery market.

Team lino Biotech AG
Dr. Mirko Stange

Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and research tool expert driven by the goal to support the development and successful commercialization of life science innovations. He has extensive founder and executive management experience in taking companies from start to success exit. Following completing his Ph.D. in Biochemistry & Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey and subsequently worked with the turn-around specialist Droege & Comp., serving mainly clients from the pharma and chemistry industry in Germany and Switzerland. In 2008 he founded an independent Life Sciences consultancy in Germany where, to date, a team of international experts identify, fund and build innovative business opportunities. To date, three co-founded companies were successfully exited. Dr. Stange is also named investor on several granted and pending patents.


Dr. Volker Gatterdam

Dr. Volker Gatterdam studied chemistry in the beautiful city of Marburg in Germany. He holds a doctoral degree with summa cum laude in biochemistry from the University of Frankfurt where he laid a solid foundation for his scientific interests. His work is focused on the chemical modifications of surfaces for the design and fabrication of biosensors. His interest in the fascinating technology of focal molography started during his PostDoc in Prof. Janos Vörös´group at ETH Zurich. His continuous passion for the technology led him to be one of the co-founders of lino Biotech. Dr. Gatterdam´s combined focal molography and business knowhow strengthens lino´s project and quality management. He is currently focussed on expanding our business network in his role as Alliance manager.


Dr. Volker Gatterdam
Dr. Andreas Frutiger

Dr. Andreas Frutiger

Dr. Frutiger has always been fascinated by the complexity of nature and driven to expand his scientific knowledge. With two masters in Material Science and Biomedical Engineering as well as a PhD in focal molography, he bridges scientific disciplines with his interdisciplinary background. Andreas Frutiger coordinates and leads lino´s internal R&D efforts to innovate disruptive biosensing products. With his key technical knowledge underlying our technology and the drive of all our team, Dr. Frutiger aims to advance biosensing in ways that are considered impossible today.


Dr. Tilman Hoss

Mr. Hoss holds a PhD in Physics from the University of Basel and an Executive MBA from IMD in Lausanne. He is an expert in product innovation and has successfully developed and launched new products in various industries. This includes products in the field of Lab Automation, Semiconductor Devices and Manufacturing Equipment or Optical Storage Media which generate well over $100 million in revenue over their product lifetimes.
With robust project management and the development of engineering and supplier networks, Mr. Hoss will help Lino Biotech's innovations enter the market.


Dr. Tilman Hoss
Charleen Thies

Charleen Thies

Ms. Thies has years of experience in marketing and communication in various industries. She is responsible for public relation and visibility of lino Biotech, digital marketing and the representation at trade fairs and conferences.
Ms. Thies will help lino Biotech enter the market, expanding the visibility.


Discover our board members.

lino's Board Members.

We  are happy to announce our board members, bringing together numerous years of experience in building life science companies, as well as licensing deals  and investment strategies.

credits: NRW.Bank

Marius Rosenberg

Marius Rosenberg is Co-Founder and Managing Director of Adhesys Medical, a high-tech medical device startup with offices in Boston, MA and Aachen, Germany. Based on the patent-protected technology platform, the company develops high-strength biodegradable surgical adhesives that can be used on the skin and inside the body. Since April 2017, Adhesys Medical is a wholly-owned subsidiary of the German pharmaceutical company Grünenthal Group. Since January 2018, the first of Adhesys’ products (Flix®) has a European-wide CE certification.
Marius has co-founded other tech startups and is a business angel investor in the high-tech and life science space. He is a Member of the Supervisory Board of Bionorica SE, Europe’s leading plant-based pharmaceutical companies and Member of the Advisory Board of RWTH Innovation GmbH, supporting high-tech startups of the RWTH Aachen University, Germany.
Prior to that, Marius has worked as a strategy consultant for The Boston Consulting Group. He studied Business Administration at the WHU – Otto Beisheim School of Management and worked as a PhD candidate at the RWTH Center for Entrepreneurship. Marius has co-authored scientific articles on Industry 4.0 and entrepreneurship topics. Father of two children, he lives in his hometown Düsseldorf.


Dr. Babette Güldenpfennig

Babette Güldenpfennig, Ph.D., joined Roche Diagnostics in 2014. She became Head of the Global Licensing Team in the same year after having supported the partnering activities of the newly established Sequencing Unit for a few months. Under her responsibility, the Licensing Team leads and conducts all licensing/partnering activities for the Diagnostic Division. In this context, Babette also drove and managed the spin-out of lino Biotech AG. Babette have brought more than fifteen years of hands-on experience in starting and managing start-up businesses to Roche having worked for Molecular Partners (listed at SIX) and Kuros Biosurgery (listed as Kuros Bioscience at SIX) which she also co-founded. As member of the executive management team of Kuros she was responsible for licensing, legal and BD matters. During that time and over the course of more than a decade, she supported the company in its maturation from the first negotiations of the foundational licensing agreements to its initial public offering. With a Ph.D. in chemistry from the ETH Zürich, Babette joined at the beginning of her career one of the largest patent law firms in Switzerland, Hepp Wenger Ryffel, where she worked as patent attorney while conducting formal training in intellectual property law.


Monique Schiersing

Monique is a Senior Investment Director at the Roche Venture Fund. Former roles include serving as the Chief Operating Officer at Inthera Bioscience AG, a previous Director position at Roche Venture Fund from 2009 to 2018, and a principal position with BankInvest's BioMedical Ventures Group in Copenhagen.
In addition, Monique's background includes several years in Roche's Pharma business development group, and various other positions in academia, biotech and venture capital, both in Switzerland and the San Francisco Bay Area. Monique holds a M.Sc. in microbiology from the University of Zurich (Switzerland) and
an MBA from the University of San Francisco.


Dr. Robert Wicke

Robert is currently CEO of Halo Labs, a life science company specializing in high-throughput protein characterization and identification. Before Halo, Robert was General Manager of Pall ForteBio responsible for growing the company from $20M to $50M+ in four years. Robert was also the Senior VP of Instrumentation R&D at Pall Corporation and a corporate M&A member, responsible for all instrumentation R&D across Pall worldwide. Robert was VP of Product Development and Operations for ForteBio from 2007 to 2012 where he helped grow the company 10x in four years and then exit the company for over $160M. Before that, Robert was at Molecular Devices Corporation, where he was Vice President of Product Development, being on the executive team that helped the $615M acquisition by MDS. Previously he was at Axon Instruments, Inc. for 13 years, as Vice President of Software Engineering, helping be the first private company to IPO on the Australian stock market, and was part of the $140+ million acquisition by Molecular Devices.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and research tool expert driven by the goal to support the development and successful commercialization of life science innovations. He has extensive founder and executive management experience in taking companies from start to success exit. Following completing his Ph.D. in Biochemistry & Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey and subsequently worked with the turn-around specialist Droege & Comp., serving mainly clients from the pharma and chemistry industry in Germany and Switzerland. In 2008 he founded an independent Life Sciences consultancy in Germany where, to date, a team of international experts identify, fund and build innovative business opportunities. To date, three co-founded companies were successfully exited. Dr. Stange is also named investor on several granted and pending patents.